Exercise rehabilitation for patients with pulmonary artery disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of a group-based outpatient exercise rehabilitation program on patients with pulmonary arterial hypertension (PAH). It aims to improve exercise capacity, quality of life, and physical activity levels among participants, following the European guidelines that recommend exercise as part of PAH treatment. The rehabilitation will be supervised by experienced professionals and tailored to fit the Finnish healthcare system. The study addresses the lack of specific outpatient exercise guidelines for PAH patients, focusing on a safe and effective rehabilitation model.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults over 18 years old residing in Tampere or nearby municipalities.
* WHO functional classification II-III.
* Commitment to the exercise program.
* Stable disease condition with no PAH medication changes in the two months prior.
* No recent syncope or arrhythmias causing symptoms within the past two months.

Exclusion Criteria:

* Severe pulmonary disease or left ventricular failure (HFrEF).
* Pregnancy.
* Severe congenital heart defect (Eisenmenger syndrome).
* Severe liver disease.
* Acute inflammatory condition.
* Severe anemia (hemoglobin ≤ 75% of the lower reference limit).
* Systolic blood pressure below 85 mmHg.
* Recent syncope.
* Other significant conditions affecting physical capacity, such as severe neurological diseases or musculoskeletal issues.
* Untreated severe arrhythmias.
* Changes in PAH medication during the rehabilitation program.

Where it's running

• Tampere Heart Hospital
  Tampere, Pirkanmaa, Finland Recruiting

Study contacts

• Study coordinator: Pauliina Leskelä, MD
• Email: pauliina.leskela@sydansairaala.fi
• Phone: +3583311611

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding how low-load leg exercises affect muscle and blood flow in PAH patients

  This substudy tests whether a gentle leg exercise program can change blood flow and oxygen use in the calf muscles of adults with pulmonary arterial hypertension.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07781709

• Sotatercept in Japanese children with pulmonary arterial hypertension

  This study tests whether sotatercept is safe and well tolerated in Japanese children with PAH when added to standard PAH treatment.

  Recruiting at 3 sites Phase 2 Merck Sharp & Dohme LLC · Izumi, Osaka and 2 other locations · NCT07646860

• DIAG723 in Adults With HHT

  A first-in-human study tests DIAG723 versus placebo in adults with hereditary hemorrhagic telangiectasia to see if it is safe and possibly helpful.

  Recruiting at 3 sites Phase 1/2 Diagonal Therapeutics, Inc. · Camperdown, New South Wales and 10 other locations · NCT07623525

• See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease

  Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.

  Recruiting Phase 3 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07613099

• Sotatercept in Indian adults with pulmonary arterial hypertension on standard therapy

  This study tests whether adding sotatercept to current PAH medicines is safe and tolerable for adults with PAH in India.

  Recruiting at 3 sites Phase 4 Merck Sharp & Dohme LLC · Hyderabad, Andhra Pradesh and 2 other locations · NCT07600723

• Once-daily treprostinil palmitil inhalation powder for PAH

  This study tests whether taking a daily inhaled treprostinil palmitil powder for 24 weeks improves exercise ability in adults with pulmonary arterial hypertension compared to a placebo.

  Recruiting at 39 sites Phase 3 Insmed Incorporated · Los Angeles, California and 38 other locations · NCT07481981

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.